Clinical Trials

1,314 enrolled

Prostatic Neoplasms

NCT07225946 2026-04-14

KLK2-PASenger

800 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT05675410 2026-04-13

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06191744 2026-04-13

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06925737 2026-04-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT06136624 2026-04-08

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

5,951 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06952803 2026-03-10

EvoPAR-PR02

700 enrolled

Prostatic Neoplasms

NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

72 enrolled

Prostatic Neoplasms

NCT06470243 2026-01-22

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

528 enrolled

Prostatic Neoplasms

NCT06006117 2025-12-19

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

260 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT06072131 2025-10-23

CRESCENDO

504 enrolled

Lymphoma, T-Cell, Peripheral

NCT06947967 2025-09-15

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

224 enrolled

Lymphoma, T-Cell, Peripheral

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

1,273 enrolled

Prostatic Neoplasms

NCT07152041 2025-09-03

CAMS-Ph+ B-ALL

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03903835 2025-04-09

ProBio

750 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03643276 2025-04-06

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

5,000 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04043494 2025-03-21

LBL 2018

683 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

500 enrolled

Genital Diseases, Male, Prostatic Diseases

NCT06284122 2024-10-15

MorningLyte

790 enrolled

Lymphoma, Follicular

NCT05351346 2023-03-24

Genotype-guided Treatment in DLBCL

1,100 enrolled